Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression

While immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape in oncology, they are effective in select subsets of patients. Efficacy may be limited by tumor-driven immune suppression, of which 1 key mechanism is the development of myeloid-derived suppressor cells (MDSCs). A f...

Descripción completa

Detalles Bibliográficos
Autores principales: Colligan, Sean H., Amitrano, Andrea M., Zollo, Robert A., Peresie, Jennifer, Kramer, Elliot D., Morreale, Brian, Barbi, Joseph, Singh, Prashant K., Yu, Han, Wang, Jianmin, Opyrchal, Mateusz, Sykes, David B., Nemeth, Michael J., Abrams, Scott I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711879/
https://www.ncbi.nlm.nih.gov/pubmed/36453551
http://dx.doi.org/10.1172/JCI158661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711879/
https://www.ncbi.nlm.nih.gov/pubmed/36453551
http://dx.doi.org/10.1172/JCI158661

Ejemplares similares